Clinical Development of Solnatide Peptide for the Therapeutic Treatment of ARDS During the Coronavirus Pandemic

Time: 12:45 pm
day: Day Two


  • Reviewing solnatide peptide and its capacity to activate pulmonary edema clearance and highlighting the molecular structure and interaction with the pulmonary ENaC channel
  • Exploring basic characteristics of ARDS patients Vs. COVID-19 patients to illuminate whether ARDS pneumonia behaves similarly to viral/COVID pneumonia
  • Navigating the limitation in hospital management during pandemics
  • Delving into clinical trials to explore what lessons can be taken away from the pandemic